Shares of Pacific Biosciences tumbled 10.8% to $1.28 as investors rushed to sell ahead of the DNA-sequencing company's Q2 2026 earnings report, scheduled for after the bell on August 5. The fear proved well-founded: PacBio fell short of revenue expectations, with sales falling 1.9% year on year to $39.01 million , and its adjusted loss of $0.14 per share was 10.4% below what analysts expected. For a company valued at roughly $447 million , another miss raises the existential question: how long can PacBio burn cash before the math breaks?

  • Revenue Is Shrinking, Not Growing, and Guidance Just Got Slashed. PacBio reported Q2 revenue of $39 million, roughly flat from $39.8 million a year earlier, while lowering its full-year revenue outlook amid a slower-than-expected rollout of its new sequencing chemistry and continued funding constraints in academic and government markets. The company had previously guided full-year 2026 revenue at $165 million–$175 million , but now expects just $155 million to $165 million. That is a downward revision in a business that needs to grow its way to survival.

  • The CEO Is Out, and the Path to Breakeven Just Got Longer. Christian Henry stepped down as CEO, with R&D and commercial leader Mark Van Oene taking over immediately. More critically, PacBio now expects to reach cash-flow breakeven in 2028, pushed back from its previous target of late 2027. With year-end cash projected at $175 million to $185 million and operating expenses still north of $215 million, the runway is finite.

  • Cost Cuts Are Real but May Not Be Enough. PacBio expects restructuring to save $15 million to $20 million in compensation costs for 2027, plus another $15–$20 million once it winds down spending on its next-generation platform. Combined, that's up to $40 million — meaningful against a $220 million expense base but not a cure for flat revenue.

  • Wall Street Still Sees Upside — On Paper. The average analyst price target is $2.98, with forecasts ranging from $1.75 to $6.00 — implying over 100% upside from today's price. But operating margin worsened to -114%, down from -113% in the year-ago quarter , and analysts see only marginal improvement, forecasting full-year losses narrowing from -$0.50 to -$0.48 per share. A stock this cheap is either a deep-value bet on genomics or a slow bleed toward dilution. Today's sellers decided not to wait to find out which.